Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2010-08-04 Interim / Quarterly Rep…
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
10-Q Filing
Interim / Quarterly Report Q2 2010
2010-08-04 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 4, 2010, reporting the issuance of a press release regarding financial results for the three and six months ended June 30, 2010. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not deemed "filed" for certain regulatory purposes. The document length is 2690 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than containing the financial results themselves. According to the MENU VS MEAL RULE, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER), as the document announces quarterly financial results via a press release.
2010-08-04 English
8-K Filing
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 18, 2010, by Insmed Incorporated. The content focuses on a notice from NASDAQ regarding the company's non-compliance with the Minimum Bid Price Rule and the potential delisting process. It includes details about the compliance period and possible outcomes but does not contain financial statements or detailed financial data. The primary subject is the notification of potential delisting and related procedural information. According to the filing definitions, this matches the category of a Delisting Announcement (DLST). The document length is 4029 characters, which is sufficient to provide substantive information rather than a mere announcement of a report. Therefore, the classification is DLST with high confidence.
2010-06-21 English
8-K Filing
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 9, 2010. It reports the submission of matters to a vote of security holders at the 2010 Annual Meeting of Shareholders, including the re-election of directors and ratification of auditors. The content focuses on the official results of shareholder votes. The document length is 2432 characters, which is relatively short and contains voting results rather than full meeting materials or detailed financial data. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2010-06-18 English
4 Filing
Director's Dealing
2010-06-11 English
4 Filing
Director's Dealing
2010-06-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.